Molecular-Targeted Therapies for Childhood Medulloblastoma

Current risk stratification of standard medulloblastoma patients is based on clinical risk factors (age between 3 and 22 years, absence of metastasis and gross total or near gross total surgical excision). In the prospective randomised HIT-SIOP PNET4 trial, two risk groups were identified according to the presence or absence of β-catenin accumulation, significant postoperative residual tumor, anaplastic/large cell histology, and c-MYC or N-MYC DNA amplification, respectively. The next European standard risk medulloblastoma trial, using biological and clinical factors for treatment stratification, is under prepar…